GlobeNewsWire
26 Mar 2026, 20:02 UTC · 26w ago
Verdict
Headline takes no side. We score KYTX +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Kyverna anticipates a BLA submission for its stiff person syndrome (SPS) treatment in the first half of 2026.
More positive than 99% of claims this week
The company holds $279.3 million in cash and equivalents, providing a projected runway into 2028.
So whatSufficient liquidity reduces the immediate risk of dilutive financing and ensures funding for the SPS launch and gMG Phase 3 trial.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 86% of claims this week
Kyverna is progressing enrollment for an FDA-aligned Phase 3 trial in generalized myasthenia gravis (gMG).
More positive than 77% of claims this week
The company reported a net loss of $161.3 million for the full year 2025, up from $127.5 million the previous year.
More negative than 71% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Company reported positive clinical data for miv-cel, a strong cash runway into 2028, and progress toward a 2026 BLA submission.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
−12.9%
Price is moving against the score
$7.00 vs $8.03 close before publication (Mar 26) · not market-adjusted
KYTX chart →
